Method of Immunization Against the 4 Dengue Serotypes

Abstract

The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, and (b) a second series of administrations of doses (i) and (ii), in which the doses (i) and (ii) are administered simultaneously at separate anatomical sites, and in which the second series (b) is implemented at least 30 days to at most 12 months after the first series (a).

1 - 13 . (canceled) 
     
     
         14 . A kit for immunization against the dengue virus, comprising a container containing at least the vaccinal dengue viruses serotypes 1, 2, 3 and 4
 (a) in the form of monovalent compositions contained in 4 separate containers, or   (b) in the form of two bivalent compositions contained in 2 separate containers.   
     
     
         15 . The kit as claimed in  claim 14 , comprising at least:
 (a) a first container containing a bivalent vaccine comprising a CYD DEN-1 and a CYD DEN-2, and   (b) a second container containing a bivalent vaccine comprising a CYD DEN-3 and a CYD DEN-4.   
     
     
         16 . The kit as claimed in  claim 14 , comprising at least:
 (a) a first container containing a bivalent vaccine comprising a CYD DEN-1 and a CYD DEN-3, and   (b) a second container containing a bivalent vaccine comprising a CYD DEN-2 and a CYD DEN-4.   
     
     
         17 . A kit for immunization against the dengue virus, comprising a container containing at least the vaccinal dengue viruses of a first serotype and of a second serotype,
 (a) in the form of two monovalent compositions contained in 2 separate containers, or   (b) in the form of a bivalent composition contained in 1 single container.   
     
     
         18 . The kit as claimed in  claim 17 , comprising at least:
 (a) a container containing a bivalent vaccine comprising a CYD DEN-1 and a CYD DEN-3, or   (b) a container containing a bivalent vaccine comprising a CYD DEN-2 and a CYD DEN-4, or   (c) a container containing a bivalent vaccine comprising a CYD DEN-1 and a CYD DEN-2, or   (d) a container containing a bivalent vaccine comprising a CYD DEN-3 and a CYD DEN-4.   
     
     
         19 . A bivalent vaccine comprising an immunoeffective amount of the vaccinal dengue viruses of a first serotype and of a second serotype and a pharmaceutically acceptable excipient. 
     
     
         20 . The bivalent vaccine as claimed in  claim 19 , comprising the vaccinal viruses selected from the group consisting of: CYD DEN-1 and CYD DEN-3; or CYD DEN-2 and CYD DEN-4; or CYD DEN-1 and CYD DEN-2; or CYD DEN-3 and CYD DEN-4. 
     
     
         21 . (canceled)